Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGRX Agile Therapeutics	$1.51	$1.49	$0.20 ▼ $2.63	$10.35M	1.58	352,864 shs	120,938 shs
ITRM Iterum Therapeutics	$0.82 +0.4%	$0.91	$0.66 ▼ $3.02	$36.47M	2.85	1.10 million shs	776,885 shs
LIAN LianBio	$0.05 -2.5%	$0.25	$0.27 ▼ $4.99	$5.40M	0.23	1.04 million shs	108 shs
RNTX Rein Therapeutics	$1.16 -3.8%	$1.47	$1.04 ▼ $4.40	$27.66M	1.31	60,633 shs	32,234 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGRX Agile Therapeutics	0.00%	0.00%	0.00%	0.00%	+3.42%
ITRM Iterum Therapeutics	+5.64%	+16.66%	-18.34%	-12.04%	-30.21%
LIAN LianBio	+2.19%	-6.73%	-87.97%	-74.34%	-84.17%
RNTX Rein Therapeutics	+1.69%	+3.90%	-20.00%	-49.15%	+119,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AGRX Agile Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ITRM Iterum Therapeutics	2.4177 of 5 stars	3.5	3.0	0.0	0.0	2.5	1.7	0.0
LIAN LianBio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RNTX Rein Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGRX Agile Therapeutics	0.00	N/A	N/A	N/A
ITRM Iterum Therapeutics	3.00	Buy	$9.00	997.56% Upside
LIAN LianBio	0.00	N/A	N/A	N/A
RNTX Rein Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGRX Agile Therapeutics	$19.98M	0.52	N/A	N/A	($5.51) per share	-0.27
ITRM Iterum Therapeutics	N/A	N/A	N/A	N/A	($0.09) per share	N/A
LIAN LianBio	N/A	N/A	N/A	N/A	$2.71 per share	N/A
RNTX Rein Therapeutics	N/A	N/A	$0.43 per share	2.68	$0.43 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGRX Agile Therapeutics	-$14.47M	-$3.65	N/A	∞	N/A	-36.24%	N/A	-147.37%	N/A
ITRM Iterum Therapeutics	-$24.77M	-$0.85	N/A	∞	N/A	N/A	N/A	-65.01%	N/A
LIAN LianBio	-$110.29M	-$0.81	N/A	N/A	N/A	N/A	-33.17%	-30.19%	N/A
RNTX Rein Therapeutics	-$62.88M	-$2.86	N/A	N/A	N/A	N/A	-86.07%	-31.11%	N/A

Latest AGRX, LIAN, RNTX, and ITRM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	RNTX Rein Therapeutics	-$0.22	-$0.28	-$0.06	-$0.28	N/A	N/A
8/5/2025	Q2 2025	ITRM Iterum Therapeutics	-$0.13	-$0.16	-$0.03	-$0.16	N/A	N/A
5/15/2025	Q1 2025	RNTX Rein Therapeutics	-$0.21	-$0.25	-$0.04	-$0.25	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGRX Agile Therapeutics	N/A	N/A	N/A	N/A	N/A
ITRM Iterum Therapeutics	N/A	N/A	N/A	N/A	N/A
LIAN LianBio	N/A	N/A	N/A	N/A	N/A
RNTX Rein Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGRX Agile Therapeutics	N/A	0.56	0.38
ITRM Iterum Therapeutics	N/A	2.69	2.52
LIAN LianBio	N/A	10.06	10.06
RNTX Rein Therapeutics	N/A	1.39	1.39

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGRX Agile Therapeutics	10.92%
ITRM Iterum Therapeutics	9.21%
LIAN LianBio	74.85%
RNTX Rein Therapeutics	90.89%

Insider Ownership

Company	Insider Ownership
AGRX Agile Therapeutics	0.50%
ITRM Iterum Therapeutics	2.40%
LIAN LianBio	7.59%
RNTX Rein Therapeutics	5.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGRX Agile Therapeutics	30	6.86 million	6.82 million	Not Optionable
ITRM Iterum Therapeutics	10	44.66 million	43.59 million	Not Optionable
LIAN LianBio	110	108.06 million	99.86 million	Not Optionable
RNTX Rein Therapeutics	9	23.05 million	21.87 million	N/A

AGRX, LIAN, RNTX, and ITRM Headlines

Recent News About These Companies

Rein Therapeutics to Present Novel IPF Science and Clinical Development Insights at IPF Summit 2025

August 14 at 5:00 PM | globenewswire.com

XtalPi and DoveTree Announce Landmark $6 Billion AI Drug Discovery Collaboration

August 7, 2025 | finance.yahoo.com

Rein Therapeutics Enters into Agreements for up to $21 Million in Flexible Financing

July 30, 2025 | finance.yahoo.com

RNTX - Rein Therapeutics Inc Dividends - Morningstar

June 26, 2025 | morningstar.comM

Rein Therapeutics Announces Adjournment of Annual Meeting of Stockholders

June 24, 2025 | prnewswire.com

US FDA puts on hold Rein Therapeutics' lung disease drug trial

June 12, 2025 | reuters.com

RNTX Rein Therapeutics Inc.

June 1, 2025 | seekingalpha.com

Rein Therapeutics, Inc.: Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF

May 27, 2025 | finanznachrichten.de

Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF

May 27, 2025 | prnewswire.com

Rein Therapeutics Presents Two Posters at the American Thoracic Society 2025 International Conference

May 19, 2025 | prnewswire.com

Rein Therapeutics, Inc.: Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 16, 2025 | finanznachrichten.de

Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 15, 2025 | prnewswire.com

Rein Therapeutics begins trial for idiopathic pulmonary fibrosis treatment

May 13, 2025 | msn.com

Rein Therapeutics, Inc.: Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPF

May 12, 2025 | finanznachrichten.de

Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPF

May 12, 2025 | prnewswire.com

Rein Therapeutics to integrate Qureight’s platform in trial of IPF treatment

May 2, 2025 | msn.com

Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF

May 1, 2025 | prnewswire.com

Rein Therapeutics to Present at The Citizens Life Sciences Conference 2025

April 30, 2025 | prnewswire.com

Rein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International Conference

April 28, 2025 | prnewswire.com

Rein Therapeutics Granted Two Patents Covering the Novel Formulation and Administration Methods of Dry Powder LTI-03 for the Treatment of Respiratory Diseases

April 23, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AGRX, LIAN, RNTX, and ITRM Company Descriptions

Agile Therapeutics NASDAQ:AGRX

Agile Therapeutics, Inc., a women's healthcare company, engages in the research, development, and commercialization of prescription contraceptive products for women in the United States. It offers Twirla, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.

Iterum Therapeutics NASDAQ:ITRM

$0.82 +0.00 (+0.42%)

Closing price 04:00 PM Eastern

Extended Trading

$0.82 +0.01 (+0.61%)

As of 07:58 PM Eastern

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

LianBio NASDAQ:LIAN

$0.05 0.00 (-2.53%)

As of 08/13/2025

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.

Rein Therapeutics NASDAQ:RNTX

$1.16 -0.05 (-3.75%)

As of 04:00 PM Eastern

Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time